Last reviewed · How we verify
VLA1553
VLA1553 is a COVID-19 vaccine.
VLA1553 is a COVID-19 vaccine. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | VLA1553 |
|---|---|
| Sponsor | Valneva Austria GmbH |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce a protective response against SARS-CoV-2, the virus that causes COVID-19.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
- Muscle pain
- Chills
Key clinical trials
- VLA1553-403 Pregnancy Surveillance Study
- Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
- A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children (PHASE3)
- Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) (PHASE3)
- A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years (PHASE2)
- A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |